Obecity drug– tag –
-
Obesity Drug Updates Part 2: Pricing and Reimbursement of GLP-1 Obesity Drugs Across Japan, the U.S., and Europe
Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ... -
Obesity Drug Updates Part 1: Novo’s Layoff and the Next Phase of GLP-1 Obesity Drugs – Innovation and Pipeline Competition
Introduction: Novo’s Layoff as a Symbol of Industry Transition In September 2025, Novo Nordisk announced a massive layoff of about 9,000 employees, roughly 12% of its global workforce. The decision comes amid intensified competition in t... -
Viking Therapeutics’ Obesity Drug Trial Sends Stock Plunging – Market Significance and Biotech Volatility
On August 19, 2025, U.S.-based biotech company Viking Therapeutics announced results from its Phase 2 trial of the oral obesity drug VK2735. While the therapy demonstrated up to 12.2% weight loss over 13 weeks, a high discontinuation rat... -
Summer Beginner Series Grand Summary Part 1｜Anti-Obesity Drugs, ADCs, and In vivo CAR-T — From Beginner to Intermediate Insights
This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modalities—anti-obesity drugs, antibody-drug conjugates (ADCs), and In vivo CAR-T cell therapy—highlighti... -
[August 2025 Update] The Frontline of the Obesity Drug Race: Lilly’s Setback, Emerging Biotechs, Big Pharma Strategies, and Chugai’s Moves
Introduction As of August 2025, the obesity drug race is undergoing major shifts. Eli Lilly and Novo Nordisk remain dominant, but biotech challengers and Big Pharma entries are redrawing the competitive map. This article reviews the late...
1